Does Cigna Cover Tresiba (Insulin Degludec)?

How Cigna Classifies Tresiba on Its Formulary

On most Cigna commercial formularies, Tresiba sits at Tier 3 (non-preferred brand) or a non-preferred specialty tier, meaning members pay a higher copay or coinsurance than they would for Tier 2 preferred insulins such as insulin glargine (Lantus, Basaglar) or insulin detemir (Levemir). Cigna's formulary structure groups basal insulins by cost-effectiveness and rebate agreements, so the exact tier can differ between an employer-sponsored PPO, an individual marketplace plan, and a Cigna Medicare Advantage plan.

The FDA approved insulin degludec in September 2015 under the brand name Tresiba, available as a U-100 FlexTouch pen and a U-200 FlexTouch pen for patients requiring higher doses. The full prescribing information lists approved indications for glycemic control in adults and pediatric patients (age 1 year and older) with type 1 diabetes, and in adults with type 2 diabetes. The American Diabetes Association 2024 Standards of Care recognize ultra-long-acting insulin analogs, including insulin degludec, as appropriate basal options when hypoglycemia risk or dosing flexibility are clinical concerns.

Tresiba's half-life exceeds 25 hours and its steady-state duration of action surpasses 42 hours in pharmacodynamic studies, which distinguishes it from insulin glargine U-100 and contributes to its lower within-person variability in glucose-lowering effect. A pharmacokinetic analysis published on PubMed confirmed this flat, stable absorption profile across a range of injection sites. Because that differentiation is pharmacological rather than purely clinical-outcomes-based, Cigna's medical policy team often still classifies Tresiba as interchangeable with glargine from a formulary-access standpoint, making prior authorization the gateway for most members.

What Cigna's Prior Authorization Criteria Typically Require

Cigna requires prior authorization for Tresiba on the vast majority of its commercial lines of business. The PA criteria generally include four elements: a confirmed diagnosis of type 1 or type 2 diabetes, documentation of current HbA1c, prescriber attestation that the patient has a clinical reason to use Tresiba specifically, and evidence of trial or contraindication to at least one preferred basal insulin.

Cigna's clinical policy bulletin for basal insulin analogs states that coverage for non-preferred long-acting insulins may be approved when "the member has tried and failed, or has a documented contraindication to, a preferred formulary basal insulin analog." Prescribers who submit medical records showing hypoglycemia events on insulin glargine, nocturnal hypoglycemia confirmed by continuous glucose monitor (CGM) data, or an insulin dose requiring the higher concentration U-200 formulation (available only for Tresiba) tend to see faster approvals.

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 reported that the rate of severe hypoglycemia was significantly lower with insulin degludec than with insulin glargine U-100: 4.9% of degludec-treated patients experienced at least one severe hypoglycemic episode versus 6.6% in the glargine group (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). DEVOTE, NEJM 2017. That published hypoglycemia advantage is exactly the kind of clinical evidence that strengthens a prior authorization request when a patient has a documented history of severe or nocturnal hypoglycemia on a preferred basal insulin.

Cigna typically processes PA requests within 3 business days for standard reviews and within 72 hours for urgent clinical situations. Approvals are valid for 12 months, after which the prescriber must submit a renewal PA demonstrating continued medical necessity and an updated HbA1c.

The ADA 2024 Standards of Care Section 9 advises clinicians to "consider insulin analogs with a lower risk of hypoglycemia for patients who experience recurrent hypoglycemia or hypoglycemia unawareness," directly supporting use of insulin degludec in that population. Quoting that guideline language in a PA submission can carry significant weight with Cigna's pharmacy reviewers.

Step Therapy: Which Insulins Cigna Requires First

Step therapy is Cigna's most common barrier to Tresiba access. Before approving Tresiba, many Cigna plans require documented use of at least one preferred basal insulin for a minimum period, typically 30 to 90 days depending on the specific plan benefit design.

The preferred step-therapy agents on most Cigna commercial formularies are:

• Insulin glargine U-100 (Lantus, Basaglar, Semglee)
• Insulin glargine U-300 (Toujeo), on some plans
• Insulin detemir U-100 (Levemir), on some plans

A prescriber can bypass step therapy by documenting one or more of the following in the PA request: an adverse reaction or allergy to a preferred agent, severe or recurrent hypoglycemia on a preferred agent (supported ideally by CGM data or emergency visit records), clinical need for the U-200 concentration that only Tresiba provides, or an existing stable response to Tresiba that predates the current plan enrollment.

FDA guidance on insulin interchangeability emphasizes that insulin products are NOT interchangeable without clinical supervision, a fact that supports the argument that a patient stabilized on Tresiba should not be required to switch to a different basal insulin purely for formulary reasons. Including a copy of the FDA communication in appeal or PA packages has helped prescribers push back against blanket step-therapy requirements.

A 2021 Cochrane review of long-acting insulin analogs found that insulin degludec reduced rates of nocturnal hypoglycemia compared with insulin glargine in type 2 diabetes, adding to the clinical differentiation argument that supports skipping step therapy in high-risk patients.

State-level step-therapy override laws also apply in many states. As of 2024, more than 30 states have enacted step therapy reform legislation requiring insurers to grant exceptions within specific timeframes when the required step-therapy drug is contraindicated or has already failed. The National Conference of State Legislatures tracks these laws, and knowing your state's law can accelerate a Cigna override request.

How to Appeal a Cigna Denial of Tresiba

Cigna denials of Tresiba fall into two categories: outright denial (not medically necessary) and step-therapy denial (preferred drug not yet tried). The appeal process is the same for both, but the documentation package differs.

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Attach the denial letter, a letter of medical necessity from the prescriber, relevant labs (HbA1c, fasting glucose logs, CGM reports), records of any hypoglycemia events, and the specific published clinical evidence supporting Tresiba's differentiation. The DEVOTE trial's hypoglycemia data cited above is particularly effective. Cigna's member appeal rights are published on its website and reproduced in every Explanation of Benefits denial letter. Cigna must issue a Level 1 decision within 30 days for prospective (pre-service) appeals and within 60 days for retrospective (post-service) appeals.

Level 2 Internal Appeal. If Level 1 is denied, file a Level 2 appeal within 60 days. Cigna routes these to a different internal reviewer, typically a physician in the relevant specialty. Adding a supporting letter from an endocrinologist at this stage substantially raises the probability of reversal. The American Association of Clinical Endocrinology (AACE) insulin management guidelines can be cited to support individualized basal insulin selection.

External Independent Review Organization (IRO). After exhausting both internal appeal levels, a member may request external review by a state-certified IRO at no cost. IRO decisions are binding on Cigna. External review overturn rates for specialty drug denials nationally run at approximately 40% to 60%, depending on the indication and the quality of the submitted clinical record. The Department of Health and Human Services maintains resources on external review rights under the Affordable Care Act.

The following decision framework summarizes when to escalate at each step.

| Situation | Best Next Action | |---|---| | First denial, no prior step-therapy trial | Submit Level 1 with hypoglycemia documentation + DEVOTE citation | | Denial because step-therapy drug "not tried" | Document contraindication or attach CGM evidence of hypoglycemia on glargine | | Level 1 upheld | Request Level 2 + attach endocrinologist letter | | Level 2 upheld | File IRO external review within 4 months | | IRO upheld | Activate manufacturer savings card while exploring plan exception or formulary exception |

A 2019 analysis in JAMA Internal Medicine found that patients who submitted appeals with physician-authored letters of medical necessity were significantly more likely to have denials overturned than those who submitted patient-authored appeals alone. JAMA Internal Medicine, 2019. That finding supports investing prescriber time in a thorough, evidence-backed appeal letter rather than relying on the patient to self-advocate.

Clinical Evidence Supporting Tresiba's Distinct Profile

Understanding the clinical trial data helps both patients and prescribers frame the medical-necessity argument clearly.

The DEVOTE cardiovascular outcomes trial enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk, randomized to insulin degludec or insulin glargine U-100, and followed them for a median of 2.0 years. DEVOTE, NEJM 2017. The primary cardiovascular endpoint (three-point MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) occurred in 8.5% of the degludec group versus 9.3% of the glargine group, meeting the pre-specified non-inferiority criterion (HR 0.91 to 95% CI 0.78 to 1.06). Severe hypoglycemia, the key secondary endpoint, favored degludec with a rate ratio of 0.60 (P<0.001 for superiority).

The SWITCH 1 trial (type 1 diabetes, N=501) and SWITCH 2 trial (type 2 diabetes, N=721) were crossover studies specifically designed to assess hypoglycemia. SWITCH 2, published on PubMed, demonstrated a 30% lower rate of overall symptomatic hypoglycemia (rate ratio 0.70 to 95% CI 0.61 to 0.80, P<0.001) with insulin degludec versus insulin glargine U-100 in type 2 diabetes. SWITCH 1 found a 11% lower rate of overall symptomatic hypoglycemia in type 1 diabetes (rate ratio 0.89 to 95% CI 0.85 to 0.94, P<0.001).

A pharmacodynamic study published by Heise et al. confirmed that insulin degludec has a coefficient of variation in glucose-lowering effect roughly four times lower than insulin glargine U-100, meaning its action is considerably more predictable between injections. Heise et al., Diabetes 2012. Greater pharmacodynamic predictability directly translates to lower hypoglycemia risk for patients with erratic schedules or those prone to missed doses.

The unique U-200 formulation delivers 200 units per mL, so patients requiring more than 80 units per day can inject half the volume compared to a U-100 product. The FDA label for Tresiba is the primary reference for dosing conversion guidance. For patients who were previously on U-200 Tresiba and now face a forced switch, the clinical and logistical difference in injection volume is a legitimate medical-necessity argument.

Out-of-Pocket Cost Options When Cigna Denies or Covers at a High Tier

The manufacturer list price for Tresiba FlexTouch pens runs approximately $510 per month for a typical dose. When Cigna places Tresiba at a non-preferred tier, cost-sharing can reach $100 to $200 per month or more, depending on the plan's non-preferred coinsurance rate.

Several cost-reduction pathways exist.

Novo Nordisk Savings Card. Novo Nordisk offers a savings card for commercially insured patients that can reduce monthly out-of-pocket costs to as low as $99 per month. The card is not valid for use with any government-funded insurance including Medicare Part D, Medicaid, or TRICARE. Eligible patients can enroll at NovoCare.com. Novo Nordisk patient assistance information confirms current eligibility rules.

NovoCare Patient Assistance Program. For uninsured or underinsured patients who meet income criteria, Novo Nordisk's patient assistance program provides Tresiba at no cost. Income thresholds and application details are available on the NovoCare website.

Formulary Exception Request. Separate from a PA appeal, a formulary exception asks Cigna to cover Tresiba at a preferred tier cost-sharing level. This requires the same medical-necessity documentation as a PA but targets the cost tier rather than access. Formulary exceptions, if granted, typically reduce member cost-sharing to the Tier 2 copay level.

GoodRx and Cash-Pay Pharmacies. Cash-pay pricing through discount platforms can bring a 3-mL box of Tresiba FlexTouch pens to approximately $200 to $300 at major retail pharmacies, which may be lower than the Cigna non-preferred copay for some plan designs. Comparing the Cigna cost-share against cash-pay pricing before filling each prescription is worth the 2-minute check.

The ADA's insulin affordability resources page aggregates manufacturer and third-party programs and is updated regularly.

Tresiba Dosing Basics for Clinical Context

Insulin degludec is dosed once daily at any time of day, with the flexibility to change the injection time between doses as long as a minimum of 8 hours separates injections. The FDA prescribing label specifies that in type 2 diabetes, the starting dose for insulin-naive patients is 10 units once daily; in type 1 diabetes, Tresiba should comprise approximately one-third to one-half of total daily insulin requirements. U-200 is unit-for-unit equivalent to U-100; the pen dial reads in units regardless of concentration, minimizing dosing error risk.

The Endocrine Society clinical practice guideline on diabetes pharmacotherapy and the ADA 2024 Standards of Care both support individualized basal insulin selection based on patient-specific factors including hypoglycemia history, lifestyle, and dose volume requirements. Citing either guideline in a PA or appeal request places the prescriber's clinical judgment in line with national specialty-society recommendations, which strengthens the case for Cigna approval.

Pediatric dosing for type 1 diabetes in patients aged 1 year and older is established in the FDA label, and the 2022 American Diabetes Association Standards of Care for Children acknowledge ultra-long-acting analogs as options in pediatric type 1 management. For pediatric patients facing Cigna denial, the age-specific indication in the FDA label is a strong rebuttal to any "not medically necessary" determination.

Medicare and Medicaid Coverage: What's Different

Cigna Medicare Advantage and Cigna Medicaid managed care plans operate under different formulary rules than commercial plans. On Medicare Part D, Tresiba is covered under a subset of Cigna's Part D formularies, typically at a higher cost-sharing tier than insulin glargine. The Inflation Reduction Act capped insulin cost-sharing for Medicare Part D beneficiaries at $35 per month per covered insulin beginning in 2023, which applies to Tresiba when it appears on the Part D formulary. CMS guidance on the $35 insulin cap explains the mechanics of this benefit.

Medicaid formularies in most states do NOT include Tresiba as a preferred product. State Medicaid programs typically default to insulin glargine U-100 as the preferred basal insulin. Prior authorization for Tresiba on Medicaid is generally more difficult to obtain than on commercial Cigna plans, and the manufacturer savings card cannot offset Medicaid cost-sharing.

Prescriber Checklist: Submitting a Winning Cigna PA for Tresiba

A complete first-submission PA package reduces the rate of initial denial and shortens the total time to patient access.

Include all of the following:

• Current HbA1c (drawn within the past 90 days)
• Diagnosis code (E10.x for type 1, E11.x for type 2)
• Documentation of current basal insulin regimen and dose
• Hypoglycemia event log or CGM report showing nocturnal or severe hypoglycemia on a preferred basal insulin, if applicable
• Attestation that the patient requires U-200 concentration, if applicable
• Reference to the DEVOTE hypoglycemia endpoint (NEJM 2017, PMID 28605603) if hypoglycemia reduction is the primary clinical reason
• Reference to the ADA 2024 Standards of Care recommendation to consider analogs with lower hypoglycemia risk for appropriate patients
• State step-therapy override law citation, if the state has enacted such legislation
• Prescriber direct phone and fax for Cigna follow-up

Submitting an incomplete PA is the single most common reason for an initial Cigna denial that could have been avoided. The Institute for Safe Medication Practices has published guidance on insulin-specific documentation standards that can serve as a secondary reference in complex cases.